Drug companies are in the midst of a glossy publicity campaign to stop attempts to control rising pharma costs. But the devil is in the details.
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
Most acquisitions by hospitals of physician practices are too small to trigger antitrust attention, study says. But a buying spree of “onesies and twosies” doctor practices has driven competition down and prices up.
Three years ago, only about a quarter of the nation’s large employers were very confident they would have a health plan in 10 years. That number has now risen to 65 percent.
Court allows state attorneys general to join a pending legal challenge to keep billions in subsidies flowing to consumers and insurers, despite the Trump administration’s resistance.
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
The Senate draft bill released Thursday to replace the Affordable Care Act risks creating a high-cost ghetto for those with preexisting conditions or long-term sickness, experts say.
Experts say the loopholes would allow states to bypass some protections for people with preexisting conditions.
Expertos en políticas de salud que han analizado el texto del proyecto de salud del Senado, aseguran que la legislación no siempre garantizaría la atención de personas con condiciones preexistentes.
One insurer is turning the tables on drugmakers with what may be a new job category: a sales force for cost-effective medicine.
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
Los peores enemigos de la Ley de Cuidado de Salud Asequible ahora están a cargo. Y están discutiendo cambios que podrían afectar a una más amplia red de planes de empleadores y a la cobertura del Medicare para los adultos mayores.
There are many ways beyond legislative repeal for the Trump administration and congressional Republicans to unravel the Affordable Care Act.
Republicans seek lower cost and more choice for health insurance sold to individuals, but cutting coverage standards could leave fewer comprehensive plans, analysts say.
The prospect of repealing the Affordable Care Act – with no replacement ready – finds many having second thoughts.
Republicans’ delay in finding common ground to repeal and replace the health law raises risks that coverage could shrink and rates rise even more, the industry says.
Employer medical insurance still covers more people than any other kind. A Republican replacement for Obamacare could spread instability beyond the health law’s shaky marketplace plans.
Price and another influential GOP congressman got a discounted deal as an Australian firm seeking federal approval sought “sophisticated U.S. investors.”
States that expanded eligibility for Medicaid have failed to enroll large numbers of a significant group that stood to benefit: ex-inmates.
Many consumers find that doctors listed in their plan’s directories aren’t accepting new patients, charge large concierge fees or may not even be in the network. Regulators don’t check.